On March 21, 2012, Dr. Burgess and twelve Members of Congress sent a letter to President Obama regarding the renewal for Texas Women's Health Program.
Read more
On March 16, 2012, Dr. Burgess and twenty-seven Members of Congress sent a letter to Chairman Rehberg and Ranking Member DeLauro, members of the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, regarding on the problems of IPAB towards Medicare.
Read more
This week, Dr. Burgess comments on Health and Human Services Secretary, Kathleen Sebelius, before the Energy and Commerce Committee to discuss the fiscal year 2013 budget. You can watch the video below. To read a transcript of the video click here.
Read more
On March 9, 2012, Dr. Burgess and twenty-five Members of Congress sent a letter to Dr. Frieden, the director of the Centers for Disease Control and Prevention, regarding the revised screening guidelines for Hepatitis C.
Read more
On March 8, 2012, Dr. Burgess and sixty-six Members of Congress sent a letter to President Obama regarding the Biologics Price Competition Act.
Read more
On March 2, 2012, Dr. Burgess sent a bipartisan letter to the Chairman of the FTC, the Honorable Jonathan Leibowitz, regarding direct interference with the state regulation of the practice of medicine.
Read more
Dr. Burgess spoke on the House Floor to recognize Rare Disease Day, which will take place on February 29, and the work of the National Institutes of Health's efforts to bring attention to rare diseases. You can watch the video below.
Read more
Washington, D.C. – Last week, Congressman Michael C. Burgess, M.D. (TX-26), Vice Chair of the House Energy and Commerce Committee’s Subcommittee on Health and Chairman of the Congressional Health Care Caucus, pressed the Food and Drug Administration (FDA) about drug shortages, specifically Doxil a chemotherapy drug, during the Energy and Commerce Subcommittee on Health hearing, “Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages.” Today the FDA announced that they will allow a temporary importation of Lipodox, a replacement for Doxil. Upon the announcement, Dr. Burgess issued the following statement:
Read more
